Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients

被引：0
|
作者：
M Wilbaux
E Hénin
A Oza
O Colomban
E Pujade-Lauraine
G Freyer
M Tod
B You
机构：
[1] EMR 3738,Department of Medical Oncology and Hematology
[2] Ciblage Thérapeutique en Oncologie,undefined
[3] Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux,undefined
[4] Université Claude Bernard Lyon 1,undefined
[5] Princess Margaret Hospital,undefined
[6] University Health Network,undefined
[7] Hôpital Hôtel Dieu,undefined
[8] Place du Parvis Notre-Dame,undefined
[9] Service d’Oncologie Médicale,undefined
[10] Investigational Center for Treatments in Oncology and Hematology of Lyon,undefined
[11] Centre Hospitalier Lyon-Sud,undefined
[12] Hospices Civils de Lyon,undefined
来源：
British Journal of Cancer | 2014年 / 110卷
关键词：
CA-125 kinetics; ovarian epithelial cancer; mathematical modelling; K–PD modelling; tumour size prediction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1517 / 1524
页数：7
相关论文
共 50 条
  • [31] Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
    Paulsen, T
    Marth, C
    Kærn, J
    Nustad, K
    Kristensen, GB
    Tropé, C
    GYNECOLOGIC ONCOLOGY, 2000, 76 (03) : 326 - 330
  • [32] CA-125 AUC as a new prognostic factor for patients with ovarian cancer
    Mano, A
    Falcao, A
    Godinho, I
    Santos, J
    Leitao, F
    Oliveira, C
    Caramona, M
    GYNECOLOGIC ONCOLOGY, 2005, 97 (02) : 529 - 534
  • [33] Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
    Herzog, Thomas J.
    Vermorken, Jan B.
    Pujade-Lauraine, Eric
    Provencher, Diane M.
    Jagiello-Gruszfeld, Agnieszka
    Kong, Beihua
    Boman, Karin
    Park, Youn Choi
    Parekh, Trilok
    Lebedinsky, Claudia
    Gomez, Javier
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 350 - 355
  • [34] THE PROGNOSTIC VALUE OF POST CHEMOTHERAPY SERUM CA-125 IN EPITHELIAL OVARIAN-CANCER
    TEELING, M
    MCGING, P
    CARNEY, DN
    IRISH JOURNAL OF MEDICAL SCIENCE, 1989, 158 (03) : 59 - 62
  • [35] PREDICTIVE VALUE OF CA-125 DURING EARLY CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER
    MOGENSEN, O
    MOGENSEN, B
    JAKOBSEN, A
    GYNECOLOGIC ONCOLOGY, 1990, 37 (01) : 44 - 46
  • [36] CA125-related Measures of Tumor Kinetics and Outcome of Patients with Recurrent Ovarian Cancer Receiving Chemotherapy: A Retrospective Evaluation
    Colloca, Giuseppe
    Venturino, Antonella
    Addamo, Gianfranco
    Coccorullo, Zaira
    Ratti, Riccardo
    Caltabiano, Graziano
    Guarneri, Domenico
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (12) : 1203 - 1209
  • [37] DIAGNOSIS OF RECURRENT OR PROGRESSIVE EPITHELIAL OVARIAN-CARCINOMA USING CA-125 AS MONITOR
    SEVELDA, P
    WAGNER, G
    WIENER KLINISCHE WOCHENSCHRIFT, 1987, 99 (21) : 768 - 770
  • [38] The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer
    Rocconi, Rodney P.
    Matthews, Kellie S.
    Kemper, Meredith K.
    Hoskins, Kelly E.
    Huh, Warner K.
    Straughn, J. Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 242 - 245
  • [39] Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel
    Bridgewater, JA
    Nelstrop, AE
    Rustin, GJS
    Gore, ME
    McGuire, WP
    Hoskins, WJ
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 501 - 508
  • [40] PREDICTION OF THE PRESENCE OF OVARIAN-CANCER BY AN IMMUNOCHEMICAL PANEL - CA-125, COPPER AND ZINC
    LISCHINSKY, S
    FRIEDMAN, M
    GAL, D
    ZINDER, O
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1988, 26 (06): : 376 - 376
12345